Experiments show promising results for a drug that could lead to a lasting treatment for millions of Americans with macular degeneration.
Researchers at the University of North Carolina School of Medicine today published new findings in the hunt for a better treatment for macular degeneration. In studies using mice, a class of drugs known as MDM2 inhibitors proved highly effective at regressing the abnormal blood vessels responsible for the vision loss associated with the disease.
“We believe we may have found an optimized treatment for macular degeneration,” said senior study author Sai Chavala, MD, director of the Laboratory for Retinal Rehabilitation and assistant professor of Ophthalmology and Cell Biology & Physiology at the UNC School of Medicine. “Our hope is that MDM2 inhibitors would reduce the treatment burden on both patients and physicians.”
The research appeared Sept. 9, 2013 in the Journal of Clinical Investigation.
As many as 11 million Americans have some form of macular degeneration, which is the most common cause of central vision loss in the western world. Those with the disease find many daily activities such as driving, reading and watching TV increasingly difficult.
Currently, the best available treatment for macular degeneration is an antibody called anti-VEGF that is injected into the eye. Patients must visit their doctor for a new injection every 4-8 weeks, adding up to significant time and cost.
“The idea is we’d like to have a long-lasting treatment so patients wouldn’t have to receive as many injections,” said Chavala. “That would reduce their overall risk of eye infections, and also potentially lower the economic burden of this condition by reducing treatment costs.” Chavala practices at the Kittner Eye Center at UNC Health Care in Chapel Hill and New Bern.
All patients with age-related macular degeneration start out with the “dry” form of the disease, which can cause blurred vision or blind spots. In about 20 percent of patients, the disease progresses to its “wet” form, in which abnormal blood vessels form in the eye and begin to leak fluid or blood, causing vision loss.
While anti-VEGF works by targeting the growth factors that lead to leaky blood vessels, MDM2 inhibitors target the abnormal blood vessels themselves causing them to regress — potentially leading to a lasting effect.
Chavala and his colleagues investigated the effects of MDM2 inhibitors in cell culture and in a mouse model of macular degeneration. They found that the drug abolishes the problematic blood vessels associated with wet macular degeneration by activating a protein known as p53. “p53 is a master regulator that determines if a cell lives or dies. By activating p53, we can initiate the cell death process in these abnormal blood vessels,” said Chavala.
The Latest on: Macular degeneration
- Fruit fly breakthrough may help human blindness research on January 18, 2018 at 4:26 am
Now, a Purdue University study has found how this light kills cells in the flies’ eyes, and that could prove a useful model for understanding human ocular diseases such as macular degeneration. Vikki Weake, assistant professor in Purdue’s Department of ... […]
- Tips for Healthy Sight on January 18, 2018 at 3:40 am
The National Eye Institute estimates that in the years between 2010 and 2050, the number of individuals affected by the most common eye disease –including age-related macular degeneration (AMD), cataracts, diabetic retinopathy, and glaucoma –“will ... […]
- Recipient wants to show appreciation for gift cards on January 18, 2018 at 2:00 am
DEAR HARRIETTE: I just learned that my mother is going blind. She has macular degeneration. She says she cannot read well and generally she sees fuzzy. I am so scared for her. She lives by herself and has been independent forever. I have invited her to ... […]
- Swollen eye is setback for blindness treatment using stem cells on January 17, 2018 at 8:07 pm
The recipient is someone with a progressive form of blindness called age-related macular degeneration. Once you are registered, New Scientist will send you our weekly newsletter, as well as occasional relevant information via email from New Scientist about ... […]
- Bionic Eye Trial Approved on January 17, 2018 at 6:58 pm
Named PRIMA, the device may help those with advanced dry age-related macular degeneration get improvements in their eyesight. The company is in talks to also conduct trials in the United States. The PRIMA implant is a photovoltaic chip about 2mm square and ... […]
- Ophthotech Begins Phase II Zimura Study in Stargardt Disease on January 17, 2018 at 7:46 am
We remind investors that following the termination of Fovista studies, after it failed in three pivotal phase III studies in wet age-related macular degeneration (“AMD”), the company is focusing on Zimura development programs. Ophthotech is already ... […]
- Diabetic Retinopathy Market will grow at 6.5% CAGR to hit $ 11 billion by 2024: Global Market Insights, Inc. on January 17, 2018 at 4:18 am
Increasing geriatric population base coupled with rising incidences of age related macular degeneration (AMD) and diabetes will drive diabetic retinopathy market over the coming years. Technological advancements pertaining to diabetic retinopathy treatment ... […]
- Ask A Doctor: What dietary changes can I make to slow macular degeneration? on January 15, 2018 at 9:10 pm
Q: What dietary changes can I make to benefit my macular degeneration? A: Certain diets in large population studies may have some effect in slowing the progression of age-related macular degeneration. Some studies suggest that eating green, leafy ... […]
- Age Related Macular Degeneration – Pipeline Review, H2 2017Overview with detailed analysis, Competitive landscape, forecast and strategies on January 6, 2018 at 2:36 am
A new independent 537 page research with title ‘Age Related Macular Degeneration – Pipeline Review, H2 2017’ guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and ... […]
via Google News and Bing News